<DOC>
	<DOCNO>NCT01095653</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-512148 ( Dapagliflozin ) improve ( decrease ) blood glucose value Asian patient Type 2 Diabetes never treat medication medication le 24 week since original diagnosis Diabetes . The safety treatment also study .</brief_summary>
	<brief_title>A Phase III Study BMS-512148 ( Dapagliflozin ) Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet Exercise</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Males female , 18 year old , type 2 diabetes inadequate glycemic control Drug naive treat antidiabetic medication &lt; 24 week Cpeptide ≥ 1.0 ng/mL Body Mass Index ≤ 45.0 kg/m² AST and/or ALT &gt; 3 time ULN Serum total bilirubin &gt; 2 mg/dL Serum creatinine ≥ 1.50 mg/dL men ≥ 1.40 mg/dL woman Creatine kinase ≥ 3 time ULN Symptoms severely uncontrolled diabetes Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>